ZUCLOPENTHIXOL ACETATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H27ClN2O2S
Molecular Weight	443.001
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1

InChI

InChIKey=OXAUOBQMCDIVPQ-IOXNKQMXSA-N

InChI=1S/C24H27ClN2O2S/c1-18(28)29-16-15-27-13-11-26(12-14-27)10-4-6-20-21-5-2-3-7-23(21)30-24-9-8-19(25)17-22(20)24/h2-3,5-9,17H,4,10-16H2,1H3/b20-6-

HIDE SMILES / InChI

Molecular Formula	C24H27ClN2O2S
Molecular Weight	443.001
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf
Curator's Comment: Description was created based on several sources, including https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987

Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2 receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Adrenergic receptor alpha-1 169 Target ID: CHEMBL2094251 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2093870 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26624987 http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.
Bipolar disorder, manic phase 6 Sources: http://www.lundbeck.com/upload/ca/en/files/pdf/pm/Clopixol.pdf https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf	Primary		Approved 8429	CLOPIXOL Approved Use Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness.

PubMed

Title	Date	PubMed
The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria.	1986 Dec	3105243
Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology.	1989 May	2732745
[acute dystonias in combined abuse of cocaine and neuroleptics].	1994 Nov 26	7990989
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Clozapine and weight gain.	2001 May	11329412
Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats.	2004 Aug	15497819
Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia.	2005 Jul	15965227
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.	2009 Nov 13	19766686
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.	2012 Apr 18	22513898

Patents

Sample Use Guides

In Vivo Use Guide

Clopixol tablets: The usual dose is 10 to 50 mg per day. Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as instructed by your doctor. Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:17:56 GMT 2023` Edited by `admin` on `Fri Dec 15 18:17:56 GMT 2023`
Record UNII	349S2ZHF05
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZUCLOPENTHIXOL ACETATE

Common Name

English

ZUCLOPENTHIXOL ACETATE [MART.]

Common Name

English

Zuclopenthixol acetate [WHO-DD]

Common Name

English

(Z)-4-(3-(2-CHLOROTHIOXANTHEN-9-YLIDENE)PROPYL)-1-PIPERAZINEETHANOL ACETATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710